Dogwood Therapeutics, Inc. (DWTX) company profile
Close on Nov 17, 2026Market cap $36.71MP/E –Yield –
About Dogwood Therapeutics
Pharmaceutical Preparations, SIC 2834
This clinical-stage biopharmaceutical company discovers and develops novel therapeutic candidates aimed at treating neuropathy and chronic pain disorders. Its development pipeline features Halneuron, a late-stage non-opioid analgesic derived from tetrodotoxin that selectively inhibits Nav 1.7 sodium channels to alleviate chemotherapy-induced neuropathic pain. Additional programs include SP16, a synthetic anti-inflammatory peptide designed to promote nerve regeneration and reduce nerve damage, alongside preclinical and clinical-stage antiviral therapies, IMC-1 and IMC-2, targeting functional somatic syndromes such as fibromyalgia and Long-COVID. Upon achieving regulatory approval, the company intends to commercialize its pipeline through pharmaceutical distribution partnerships targeting primary care physicians, oncologists, and anesthesiologists.
The enterprise operates as a development-stage entity without commercial revenue and conducts operations across North America and international territories through subsidiaries including Wex Pharmaceuticals, Inc. It oversees clinical development programs across multiple locations, including Phase 2b trial sites in the United States. Technical development activities incorporate contract research and manufacturing relationships with an overseas active ingredient supplier and a Canadian fill-and-finish facility. The provided text does not identify corporate headquarters.
Summary of the business section of Dogwood Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Dogwood Therapeutics, Inc.
- Headquarters
- Alpharetta, GA
- Address
- 44 Milton Avenue 30009
- Phone
- (866) 620-8655
- Website
- dwtx.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Forvis Mazars, LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- DWTX
- Former tickers
- VIRI until Oct 30, 2024
- Exchange
- Nasdaq
- IPO date
- Dec 18, 2020
- Shares outstanding
- 34M, Aug 13, 2026
- Public float
- $8.09M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Oct 9, 2024
- SEC CIK
- 1818844
- CUSIP
- 92829J203
- ISIN
- US92829J2033
- FIGI
- BBG00X0SZKJ2
- Share class FIGI
- BBG00X0SZLB8
- EIN
- 85-4314201
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER, Director | 57,461 |
| Roger Michael Gendreau | CHIEF MEDICAL OFFICER | – |
| Ralph Grosswald | SVP OF OPERATIONS | – |
| Angela Walsh | Chief Financial Officer | 3,000 |
| Inc. Conjoint | Director | 24,664,971 |
| Ltd Sealbond | Director | 28,763,331 |
| Life Sciences Intl (Holdings) Inc CK | Director | – |
| David R. Keefer | Director | 12,808 |
| John C. Thomas | Director | 1,000 |
| Richard James Whitley | Director | 700 |
| La Rosa Abel De | Director | 4,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.34M | $2.62M | $1.29M | $17 | – |
| FY2024 | $881.22K | $751.88K | $437.97K | $29 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Greg Duncan Chairman and Chief Executive Officer | $577.00K | $2.40M | $317.35K | $49.78K | $3.34M | +280% |
| R. Michael Gendreau, MD, PhD Chief Medical Officer | $366.08K | $779.14K | $146.43K | $38.62K | $1.33M | +160% |
| Angela Walsh Chief Financial Officer | $300.91K | $779.14K | $128.76K | $43.24K | $1.25M | +244% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 18, 2020
- Offer price
- $10.00
- Securities offered
- 3,000,000
- Gross proceeds
- $30.00M
- Exchange
- Nasdaq
- First trading day
- Dec 17, 2020
- First-day close
- $16.71+67.1%
- Lock-up ends (est.)
- Jun 15, 2021
“We are offering 3,000,000 shares of our common stock at an initial public offering price of $10.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight full-time employees and no part-time employees with five employees working in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 21, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 15, 2024 | Name change | Name changed from Virios Therapeutics, Inc. to Dogwood Therapeutics, Inc. |
| Oct 7, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 12, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 7, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 7, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 2, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 3, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 18, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 16, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 16, 2020 | Name change | Name changed from Virios Therapeutics, LLC to Virios Therapeutics, Inc. |
See a number that looks wrong?